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Abstract
Purpose: We propose a process of quality assurance to validate and implement the single isocenter technique for breast cancer
radiotherapy. We evaluated the dosimetric and temporal gains using the single isocenter technique compared to classic source
to skin distance (SSD) technique. Methods: 6 patients of breast cancer localization were studied. For each patient 2 treatment
plans were generated. In plan 1 the dose was calculated using SSD technique. In plan 2 the dose was calculated using single iso-
center technique. To implement the plan 2 a dosimetric analysis including monitor units (MU), isodose curves, cumulative and
differential dose volume histograms cDVH, dDVH respectively, coverage index, conformity index for planning target volume
were used. The measurements using a PMMA phantom consist of measuring point dose by an ionization chamber and 2D dose
distributions using 2D diodes arrays. Wilcoxon signed rank and Spearman’s tests were used to calculate p-value and correlation
coefficient, respectively. Results: The single isocenter technique reduced the MU by average on -30.1 ± 13.6%, (p = 0.03). We
observed an improvement with statistical significance between the two techniques for the mean dose, minimum dose and vol-
ume receiving 95% of the prescribed dose without over-dosage. The analysis for dDVH showed that the dose distribution in the
target volume calculated in the single isocenter technique is more homogeneous than the SSD technique. Wilcoxon test showed
that the two treatment plans had the same quality (p > 0.05). The difference between calculated and measured dose was within
2.4 ± 3.3% for absolute point dose and the percentage of points passing gamma criteria was on average 99.8 ± 0.2%. Conclusion:
This method provides a quantitative evaluation and comparison of the two irradiation techniques for breast cancer and the
consequences of the technical change on dose calculation.
Keywords:Breast Cancer; Single Isocenter; Radiotherapy
Introduction
The classic source to skin distance (SSD) technique for breast
cancer treatment combines from 2 to 7 irradiation fields. An
operator needs to enter the treatment room and change the
patient position for the next treatment field. Hence, this
technique is rather time consuming, but also introduces po-
tential positioning errors that may lead to over or un-
der-irradiation.1, 2 This technique looks rather old fashion at
the present time where up to date, linear accelerators allow
complex volume irradiations from a single isocenter as for
intensity-modulated radiation therapy (IMRT) and volumet-
ric-modulated arc therapy (VMAT). Using a single isocentric
technique (SIT) would be more relevant, all treatment fields
would have the same isocenter, and the patient a unique
position thus reducing the positioning variability and impr-
oving the reproducibility of treatment fields junctions.3, 4, 5, 6
The switch from SSD to SIT is thus desirable but immediate-
ly raises the question of the equivalence of results and toler-
ance. Although, breast cancer is a frequent condition, it
looks inappropriate to design randomized comparative trials
having clinical issues as end point, to solve this question.
According to the very fundamental principle of radiation
therapy: Similar doses should yield similar effects. So a com-
parative analysis based on dosimetric comparative tools
originated from quality assurance methods could help to
solve this problem and provide to the radiation oncologists’
clues solid enough to switch for SIT with or without adapta-
tions of their prescriptions references.
In this study we will assess the impact of switching from the
SSD technique to the SIT on dosimetry parameters including
the total radiation time delivery (in terms of monitor units)
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in the case of breast cancer treatment. This has been
achieved by appraising the discrepancies between these two
techniques using statistical analysis of dosimetric data ob-
tained from real clinical treatments.
Methods and Materials
Clinical cases
This study is based on 6 patients with breast cancer
including 19 planning target volumes (PTV). These patients
were chosen to cover the range of the different types of
clinical situations, namely: Breast alone, breast with boost,
breast and internal mammary chain (IMC) or IMC and
supra-clavicular area. Table 1 shows the site locations, the
number of PTV, the prescribed dose and the treatment fields
for all patients. Clinicians delineated the anatomic borders of
target structures and organs at risk (OAR).
Planning CT-scans and contouring of
structures
The computed tomography (CT) images of each patient were
loaded into the treatment planning system (TPS) Eclipse®
(Varian, version 8.9). The virtual simulation for each patient
was generated by a digitally reconstructed radiograph (DRR)
and beam's eye view (BEV) information. Thus a treatment
field was superimposed on the DRR to assess target
localization. The target volume including the security
margins and the organs at risk were jointly defined by the
radiation oncologist and the medical physicist. In order to
take into account the patient respiratory movements and
possible positioning errors, a 7 mm margin was added to each
of these clinical target volumes.
TABLE 1: Report of the site locations, the number of PTV, the prescribed dose and the treatment fields for all patients.
Patients PTV Prescribed dose /
dose per fraction [Gy]
Energy Fields
1 Breast 50.6 /2.2 6MV 2 internals tangential
2 externals tangential
Supra clavicular 50.6 /2.2 6MV 1 interior








Supra clavicular 48.3 / 2.1 6 MV
18MV
2 interiors
Boost 11.5 / 0.5 18MV 1 internals tangential
1 externals tangential
3 Breast 50.6 / 2.2 6 MV 2 internals tangential
2 externals tangential
Supra clavicular 48.3 / 2.1 6 MV 1 anterior








Supra clavicular 50.6 / 2.2 6 MV
18MV
2 anteriors




Supra clavicular 50 / 2 6 MV 1 anterior












Supra clavicular 46.2 / 2.1 6MV 1 anterior
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FIG. 1: Comprehensive quality assurance method including three successive steps to validate and implement the isocenter technique for breast
cancer.
FIG. 2: Two opposed tangential fields to treat mammary gland using a wedge and an additional area such as boost. The left panel corresponds to
the mammary gland area in orange, and right panel to boost area in yellow color.
FIG. 3: One anterior photons and electrons beams to treat IMC area, and one anterior photons beam to treat supra-clavicular area. The left panel
corresponds to IMC area in blue color, and right panel to supra-clavicular area in green color. Green point shows the beam entrance on the
patient skin.
Quality assurance method for implementing
the single isocenter technique (SIT)
The implementation and validation of the SIT consists of 3
successive steps including the generation of 2 treatment
plans, the dosimetric and the statistical analysis, as shown in
Figure 1.
Treatment planning
For each patient, two treatment plans were generated using
Eclipse® TPS:
 In plan 1 the dose was calculated using the SSD
technique which was taken as the reference one,
as shown in Figure 2 and 3. Patients were treated
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using the monitor units computed for this plan.
 In plan 2 the dose was calculated using the SIT.
The SSD technique was carried out as following: A CT was
performed in treatment position, then the limits of the target
volumes, namely the PTV, were drawn with the imaging
tools of the Advantage Window® station (General Electric,
USA). Crawling through the transverse images, the level of
the thickest part of the breast was chosen to position the
reference axis of the beams thus allowing to define the
entrance point of both tangential beams axis. These points
were marked on the patient’s skin and pictures were taken.
Using these data, the planification was completed using
Eclipse® TPS to make the dosimetric SSD plan and to
calculate the beam parameters. At last, the dosimetric project
was validated and verified respectively by the radiation-
oncologist and the medical physicist.
The dose was computed in plan 1 and plan 2 with the
modified Batho correction density method in combination
with the pencil beam convolution algorithm. To implement
the beam configurations for SIT, the same CT images as for
plan 1 were used with the same dose constrains for organs at
risk as for plan 1. Figure 2 shows two opposed tangential
fields to treat mammary gland and an additional boost using
a wedge. As shown in the left and right panels, the
mammary gland and boost were treated with 2 beams and
presented in orange and yellow colors, respectively. Figure 3
shows one anterior photons and electrons beams to treat
IMC area, and one anterior photons beam to treat
supra-clavicular area. The left panel corresponds to IMC area
in blue color, and right panel to supra-clavicular area in
green color.
FIG. 4: Visualization of the position of the single isocenter,
represented as a red point, on the projection of the irradiation fields
placed on the skin of the patient. The unique isocenter was
positioned on the patient skin. In the left panel, the unique isocenter
positioned at the junction of the tangential to treat the breast, IMC
and supra-clavicular areas represented in orange, blue and green
respectively. In right panel, the unique isocenter was positioned on
the patient skin at the field’s junction for treat breast and
supra-clavicular areas presented in orange and green colors
respectively.
The isocenter was positioned according to the anatomical
area to be irradiated. In the case of treatment of breast, IMC
and supra-clavicular areas all together, the unique isocenter
was positioned on the patient skin, at the junction of the
tangential, IMC and supra-clavicular fields, as shown in
Figure 4 (left panel). In the case of two areas treatment, the
isocenter was positioned on the patient skin, at the field’s
junction, as shown in Figure 4 (right panel). The contoured
target volumes on the computed tomography images allowed
an optimal positioning of that isocenter. Figure 4 shows the
position of the single isocenter, represented as a red point, on
the projection of the radiation fields on the patient's skin.
The geometrical parameters of each beam were then defined
using the same type of field as with the SSD technique but
without the wedges for they cannot be used with the single
isocenter technique. Indeed, tangential fields are generated
from a quarter of a beam and since the wedges are of limited
size, they cannot fill up the entire tangential field area.
Therefore, to obtain an homogeneous distribution of dose in
the target volume, we used the “field-in-field” technique.7, 8
With this technique the mammary gland is treated by two
opposed tangential beams using the multi-leaf collimator
(MLC) to protect areas where overdoses were observed. The
shape of the MLC was defined using the BEV, and beams
weight and energy were optimized as well as the
normalization point position. Finally, we made sure that the
collimator rotation was equal to zero degree for all fields, to
avoid generating depth overlap and to make a perfect
junction between the fields.
Dosimetric analysis
Comparison of calculated dose
Monitor units (MU)
The MU characterizes the irradiation duration. The
calculation of the average and SD had been performed by
summing MU for plan 1 and plan 2 for each patient and
averaging with respect to the number of patients (n = 6).
Isodose curves
The 95% and 100% isodose curves encompass the PTV.
Dose volume histogram (DVH)
For each PTV the minimum dose (Dmin), mean dose
(Dmean), maximum dose (Dmax), as well as the calculated
dose to 95% of the PTV volume (D95) and the volume of PTV
receiving 95% of the prescribed dose (V95) were compared
using cumulative DVH (cDVH). The differential DVH
(dDVH) was used to compare the dose homogeneity inside
the PTV using the standard deviation (S-index). Lastly we
make sure that the dose tolerances of the three major organs
at risk (OAR), i.e. lungs, spinal cord and heart, were met. For
each of these organs and for each technique, the Dmean and
Dmax were compared.
For each patient, to compare plan 2 with plan 1, the
calculated dose in plan 1 was taken as the reference values.
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The difference in percentage was calculated as:
ΔDose (%) = (Dplan2 - Dplan1) x 100 / Dplan1 (1)
The positives values mean that the calculated dose using plan
2 (SIT) was higher than the calculated using plan 1 (SSD) and
negative values would mean the opposite (Dplan2 < Dplan1).
Quality indexes
The coverage index (CI) and conformity index for planning
target volume (CIP) were compared using the following
equations 9:
CI = (2)
Where, Imin is the minimal isodose surrounding the target
and RI is the reference isodose.CIP = (3)
Where, TV59% is target volume (TV) covered by the
reference isodose 95%.
Comparison of calculated dose with measured dose
In order to validate the single isocenter technique we make a
consistent comparison for calculated dose with Eclipse® TPS
and measured dose under the accelerator in the same
condition. For this objective patient specific intensity-
modulated radiation therapy quality assurance (IMRT-QA)
methods have been used to validate the SIT. The QA for
IMRT consists of measuring point doses and 2D dose
distributions. The measurements were carried out according
to AAPM (American Association of Physicist in Medicine)
and ESTRO (European Society for Radiotherapy &
Oncology) guidelines.10, 11 To compare the calculated dose
with measured dose a CT-Scans of solid water slabs (30 × 30
× 15 cm3) was used.
Measuring point dose
The pinpoint chamber 0.0125 cc was used. To measure the
dose, the ballistic of plan 2 with the SIT was used. All
parameters of the treatment plan were applied, a part of the
gantry angle which was equal to 0 degree. The measurement
was done using a Clinac600® accelerator and the detectors
placed at 5 cm depth in the phantom. The distance between
the source and dosimeters was 100 cm along the beam axe.
For each field the calculated dose was compared with the
measured dose for three specific points. These points were
selected in the flat domain of the dose profile calculated with
the TPS. The difference between calculated dose (Dc) and
measured dose (Dm) was calculated as follows:
ΔD % = (Dm - Dc) × 100 / Dc (4)
The treatment plan was validated if 2 points upon 3 show
less than 3% of difference.
2D dose distributions
The dose distribution showing a planar fluency map at 5 cm
depth from the slab surface was calculated in the TPS and
exported for comparison with the measured dose
distribution. To compare the fluency map obtained from the
TPS with dose fluency delivered by the accelerator, a
2-dimensional diode array (MapChek®, Sun Nuclear, USA)
was used. This detector is used for QA tests in IMRT. The
dose measures were done taking account of the background
correction factors and after the calibration procedure for the
detector. The measurement of fluency map was carried out
using a 0° beam incidence to avoid the dependence of
MapChek® detector on beam incidence. Consistency of
measurements and calculation was assessed using the γ index
with criteria of (3%, 3 mm). In this case the treatment plan
was validated if 97% of the considered pixels were < 1.
Statistical analysis for dosimetric data
Wilcoxon signed rank test was used to calculate the p-value.
A bilateral statistical test was realized with an error α = 5%,
corresponding to a 95% confidence interval. The dose dif-
ference is considered significant if p < 0.05. Data are pre-
sented as average ± standard deviation (SD). The
box-and-whisker, boxplot, method was used to display the
data set of 6 patients including all PTV (n = 19). Boxplot
shows the minimum, maximum values as well as the 25th,
50th (median) and 75th percentile. The statistical correlation
between calculated and measured dose was evaluated using
Spearman’s correlation coefficient. Correlation test can be
used to measure the strength of the relationship between
measured and calculated dose, i.e. estimate how much meas-
ured and calculated dose are related.12 The average difference
between calculated and measured dose with SD were used to
calculate the confidence limit CL:
CL = |average| + 1.96 × SD (5)
For the gamma analyses, where perfect agreement produces
a passing rate of 100%, the confidence limit is defined as:
CL = (100 - average) + 1.96 × SD (6)
where, average is the percentage of points passing the




The SIT reduced the MU by average on (-30.1 ± 13.6%) with
a median of -31.5% and (p = 0.03). This lower MU number is
due in part to the fact that the SIT needs less numerous
beams and in part to the collimator opening which is
different for SIT.
Isodose curves
In the transversal plans, we observed that both 95% and 100
% isodose curves enclose the same fraction of PTV using the
two techniques.
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Dose volume histogram
Figure 5 shows boxplot for cDVH indicating the minimum
median and maximum values, the 25th and 75th percentile.
The SIT reduced the under-irradiated volume D95% by
average on (-7.36 ± 23.3%) with a median of 2.5% and (p =
0.01). In the case of V95%, we observed a mean difference of
1.3 ±14.4% with a median of 2% and (p = 0.01). The analysis
of the dDVH showed that the dose distribution within PTV
was more homogeneous with the SIT than with the SSD one.
A mean difference for S-index of (-7.2 ± 45.3% with median
of -11.4% was observed. The Wilcoxon test supported the
significance of this improvement (p < 0.001). For OAR the
Table 2 shows dosimetric and statistical results obtained for
lung, heart and spinal cord. For normal lung the dose
constraints V20 < 30% and V30 < 20% were respected. The
dose constraint for heart (maximum dose ≤ 35 Gy) and spinal
cord (maximum dose ≤ 45 Gy) were respected in all plans.
TABLE 2: Dose difference for parameters deriving from dose volume histograms for organs at risks in all patients. ΔDose % was calculated
according to equation 1, the negative sign means that SIT values are lower than SSD values. SD is the standard deviation. The p-values were




contralateral Heart Spinal cord
Dmax Average ± SD -2.1±4.3 - 8±32 3 ±16.4 - 13.3±34.9
Median - 2.9 - 10 -2.6 - 13
p-value 0.4 0.2 0.7 0.3
Dmean Average ± SD -8.2±8.7 -3.0±12.8 17.6±23.1 - 2.4±9.9
Median - 6.9 0.6 25.9 0.9
p-value 0.1 0.3 0.2 1
FIG. 5: Boxplot for dose difference obtained from cDVH parameters
indicating the minimum, median in red line and maximum values, as
well as the 25th and 75th percentiles. The median values of dose
difference is close to zero for Dmean and Dmax.
FIG. 6: Boxplot for quality indices indicating the minimum, median
in red line and maximum values, as well as the 25th and 75th
percentiles. The CI and CIP indices have the same median values for
both techniques which have thus the same quality indices.
Quality indices
The comparison of CI and CIP showed that both techniques
have the same quality. The averages of CI were 0.2 ± 0.3 and
0.3 ± 0.4 for plan 1 in SSD and plan 2 in SIT, respectively.
The averages of CIP were 0.6 ± 0.2 and 0.7 ± 0.3 for plan 1
with SSD and plan 2 with SIT, respectively. Wilcoxon test
showed that both techniques have the same dosimetric
quality regarding CI and CIP indices with p = 0.22 and p =
0.27 respectively. Figure 6 represents the indices values using
boxplot representation. It is clear that the CI has a median of
0.1 for both techniques. The CIP has a median of 0.6 and 0.7
for plan 1 and plan 2 respectively
Discrete dose measurements
For absolute point dose, the tolerance condition for 2 points
among 3 having 3% or less of difference was respected. The
difference between calculated and measured dose was within
2.4 ± 3.3% and CL was 8.86%, p = 0.02 with strong
correlation r = 0.99. By using  criteria of (3%, 3 mm) for 2D
dose analysis, we observed that the percentage of points
passing the gamma criteria was on average 99.8 ± 0.2% with
CL = 0.76%.
Discussion and Recommendations
The irradiation duration in MU for the set of treatments is
substantially shorter with SIT than with SSD one (p < 0.001).
When analyzed by localizations, we were able to determine
that the duration mainly decreased for the tangential beams
treating the mammary gland. Since the time spent by the
patient under the beam is critical for the economic efficiency
of a radiotherapy department, this reduced number of MU is
a valuable contribution to the advantages of the SIT. The
cDVH and dDVH analysis for all patients showed a
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significant improvement (p < 0.05) using SIT in terms of
maximum and mean doses, under-dosage, V95% and
delivered dose homogeneity to the target volume. Again,
identifying the PTV locations, we observed that the
significant improvements were for the supra-clavicular and
the mammary gland areas. No statistically significant
differences were observed for quality indices, (p > 0.05).
The CI and CIP indices provide a qualitative comparison
between plan 1 and plan 2. The indexes quantify the degree
of congruence between isodoses and prescribed dose. A care
should be taken during interpretation the indices, since small
changes in the dose distribution can dramatically change the
conformity values. The s-index associated with dDVH
provides a more reliable and accurate measure of dose
homogeneity within the PTV.
Using single isocenter treatment plan, the calculated doses
with TPS confirmed the results obtained for dose
measurements. The AAPM suggested 4.5% for the CL
between calculated and measured dose using ionization
chamber. We observed a CL > 4.5% for all absolute dose
measurements, but considering only the tolerance 2/3 of
points having 3% the CL was < 4.5%.
This study has however several limitations. The main
limitation is the number of patients. Nevertheless, Wilcoxon
test can be used to calculate p-values for this small sample
size. We were also confronted to a limit of the single
isocenter technique when implementing the beam
configurations. Indeed, the field size is limited since it used
only the half of the maximum aperture size of the collimator
jaws which is 20 cm on each side of the isocenter. This could
be an issue to properly treat the lower limit of a large
mammary gland.
To verify the implementation feasibility of the single
isocenter technique, we recommend the following
procedures:
 Localizing the normalization point of each field at
1cm or more from the collimator blades to avoid
the penumbra zones.
 Using an equivalent square field of, at least, 4 × 4
cm² at the source-axis distance, smaller fields are
not modeled.
 Using the field-in-field technique to obtain a
homogeneous dose distribution in the PTV when
IMRT is not used.
 Verifying the number of MU with independent
computation.
 Verifying the enforcement of dose constraint for
target volumes and OAR.
 QA by the measurement using IMRT-QA program
to compare with the TPS calculated dose.
Conclusion
This paper presents a global approach for QA to implement
the single isocenter method. This approach is based on dosi-
metric and statistical analysis methods. It enables the physi-
cist and the radiation oncologists to be aware of treatment
modifications associated with the change of SSD technique
to single isocenter technique. We observed a reduction of
irradiation duration and an improvement of the dose distri-
bution homogeneity in the target volumes (p < 0.05) with
the single isocenter technique. In addition no difference
between treatment plan quality or healthy tissue and OAR
preservation have been established (p > 0.05). The confi-
dence limits of methods for measuring the point doses and
2D dose distributions were in accordance with AAPM and
ESTRO guidelines. Therefore, the usage of the single isocen-
ter technique could be considered in the radiation oncology
department with full confidence.
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